Actuate Therapeutics, Inc. (ACTU)
NASDAQ: ACTU · Real-Time Price · USD
5.91
+0.03 (0.51%)
Nov 14, 2025, 4:00 PM EST - Market closed

Actuate Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22
Selling, General & Admin
12.526.483.273.82
Research & Development
11.8518.6821.7116.39
Operating Expenses
24.3725.1624.9720.21
Operating Income
-24.37-25.16-24.97-20.21
Interest Expense
-0.02-0.02-0.04-0.02
Interest & Investment Income
0.270.220.350.03
Other Non Operating Income (Expenses)
--0.08-0.080.04
EBT Excluding Unusual Items
-24.12-25.04-24.74-20.16
Other Unusual Items
--2.25--
Pretax Income
-24.12-27.29-24.74-20.16
Net Income
-24.12-27.29-24.74-20.16
Net Income to Common
-24.12-27.29-24.74-20.16
Shares Outstanding (Basic)
20811
Shares Outstanding (Diluted)
20811
Shares Change (YoY)
418.68%483.48%18.54%-
EPS (Basic)
-1.20-3.26-17.24-16.65
EPS (Diluted)
-1.20-3.26-17.24-16.65
EBIT
-24.37-25.16-24.97-20.21
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q